Navitoclax (ABT-263)

Navitoclax (ABT-263) represents one of the most studied senolytic compounds in preclinical research, originally developed by AbbVie as a cancer therapeutic targeting BCL-2 family proteins. Research indicates that this small molecule can selectively eliminate senescent cells by disrupting their enhanced dependence on anti-apoptotic BCL-2 and BCL-xL proteins for survival. Studies suggest that senescent cells accumulate these protective factors to resist natural cell death, making them vulnerable to BCL-2/BCL-xL inhibition while leaving healthy cells relatively unaffected.

Preclinical studies have shown promising results across multiple models of aging and age-related diseases, with research indicating potential benefits for fibrosis, metabolic dysfunction, and neurodegeneration. However, clinical development as a senolytic has been limited by significant dose-limiting toxicity, particularly severe thrombocytopenia (platelet reduction) caused by BCL-xL inhibition in platelets. This side effect has proven challenging in cancer trials and remains a major barrier for healthy aging applications.

While navitoclax continues to be investigated in clinical trials for various cancers, its use as an anti-aging intervention remains purely experimental. The compound is not available outside of clinical trials, and its significant toxicity profile makes it unsuitable for general longevity applications. Research suggests that future senolytic development may focus on more selective compounds or intermittent dosing strategies to minimize adverse effects while maintaining senescent cell clearance.